ACOG (Alpha Cognition) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Alpha Cognition's annualized Gross Profit for the quarter that ended in Dec. 2024 was $0.00 Mil. Alpha Cognition's average Total Assets over the quarter that ended in Dec. 2024 was $27.88 Mil. Therefore, Alpha Cognition's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.

Alpha Cognition Gross-Profit-to-Asset % Historical Data

The historical data trend for Alpha Cognition's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Gross-Profit-to-Asset % Chart

Alpha Cognition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Alpha Cognition Quarterly Data
	Jan20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Alpha Cognition's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Alpha Cognition's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpha Cognition's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Cognition's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Alpha Cognition's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Alpha Cognition Gross-Profit-to-Asset % Calculation

Alpha Cognition's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	0	/	( (2.452	+	50.737)	/ 2 )
	=	0	/	26.5945
	=	0.00 %

Alpha Cognition's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	0	/	( (5.028	+	50.737)	/ 2 )
	=	0	/	27.8825
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Alpha Cognition Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpha Cognition Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (NAS:ACOG) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 - 750 West Pender Street, Vancouver, BC, CAN, V6C 2T8

Website

https://www.alphacognition.com

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.